Early palliative care reduces hospital readmissions by 23% for patients with cancer
the ONA take:
According to a new study presented at the American Society of Clinical Oncology (ASCO) Palliative Care in Oncology Symposium in Boston, Massachusetts, researchers at Duke University Hospital in Durham, North Carolina, have designed a collaborative approach in cancer care that decreased the number of patients readmitted to the hospital or sent to intensive care.
Their new treatment model consists of medical oncologists and physicians specializing in palliative care rounding together to care for patients with solid tumors. The two types of physicians met multiple times a day to review their patients' care.
Then, the researchers reviewed the 2,353 inpatient encounters that the cooperative team rounded on since 2011. Their analysis showed that there was a 23% reduction in the number of patients readmitted within 1 week of discharge. They also found a 15% reduction in the number of patients transferred to intensive care. The collaborative team model also allowed patients to be discharged approximately 8 hours sooner and hospice referrals rose 17%.
The findings suggest that implementing palliative care sooner in patient care, rather than prolonging palliative care until disease progression, will allow patients to talk about their desired quality of life earlier. The researchers hope to also conduct cost-benefit analyses.
Researchers designed a collaborative approach that decreased the number of patients readmitted.
Doctors at Duke University Hospital have developed a new collaborative model in cancer care that reduced the rates at which patients were sent to intensive care or readmitted to the hospital after discharge. The Duke researchers shared their findings today at the Palliative Care in Oncology Symposium sponsored by the American Society of Clinical Oncology.
In the new treatment model, medical oncologists and palliative care physicians partnered in a "co-rounding" format to deliver cancer care for patients admitted to Duke University Hospital's solid tumor unit. The Duke model fostered collaboration and communication between the specialists, who met several times a day to discuss patient care.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|